PMID- 29150352
OWN - NLM
STAT- MEDLINE
DCOM- 20190912
LR  - 20211204
IS  - 2212-4934 (Electronic)
IS  - 2212-4926 (Print)
IS  - 2212-4926 (Linking)
VI  - 67
DP  - 2018 Jan
TI  - Dysregulation of mRNA translation and energy metabolism in cancer.
PG  - 30-39
LID - S2212-4926(17)30170-7 [pii]
LID - 10.1016/j.jbior.2017.11.001 [doi]
AB  - Dysregulated mRNA translation and aberrant energy metabolism are frequent in 
      cancer. Considering that mRNA translation is an energy demanding process, cancer 
      cells must produce sufficient ATP to meet energy demand of hyperactive 
      translational machinery. In recent years, the mammalian/mechanistic target of 
      rapamycin (mTOR) emerged as a central regulatory node which coordinates energy 
      consumption by the translation apparatus and ATP production in mitochondria. 
      Aberrant mTOR signaling underpins the vast majority of cancers whereby increased 
      mTOR activity is thought to be a major determinant of both malignant translatomes 
      and metabolomes. Nonetheless, the role of mTOR and other related signaling nodes 
      (e.g. AMPK) in orchestrating protein synthesis and cancer energetics is only 
      recently being unraveled. In this review, we discuss recent findings that provide 
      insights into the molecular underpinnings of coordination of translational and 
      metabolic programs of cancer cells, and potential strategies to translate these 
      findings into clinical treatments.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Leibovitch, Matthew
AU  - Leibovitch M
AD  - Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC, H3T 1E2, Canada. 
      Electronic address: matthew.leibovitch@mail.mcgill.ca.
FAU - Topisirovic, Ivan
AU  - Topisirovic I
AD  - Gerald Bronfman Department of Oncology, Montreal, QC, H3A 1A3, Canada; Department 
      of Biochemistry, Montreal, QC, H3A 1A3, Canada; Department of Experimental 
      Medicine McGill University, Montreal, QC, H3A 1A3, Canada; Lady Davis Institute, 
      SMBD JGH, McGill University, Montreal, QC, H3T 1E2, Canada.
LA  - eng
GR  - R01 CA202021/CA/NCI NIH HHS/United States
GR  - MOP-115163/Canadian Institutes for Health Research/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171102
PL  - England
TA  - Adv Biol Regul
JT  - Advances in biological regulation
JID - 101572336
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - *Energy Metabolism
MH  - Humans
MH  - Neoplasm Proteins/*biosynthesis/genetics
MH  - Neoplasms/genetics/*metabolism/pathology
MH  - *Protein Biosynthesis
MH  - RNA, Messenger/genetics/*metabolism
MH  - RNA, Neoplasm/genetics/*metabolism
MH  - TOR Serine-Threonine Kinases/*biosynthesis/genetics
PMC - PMC5993950
MID - NIHMS972376
OTO - NOTNLM
OT  - Cancer
OT  - Energy metabolism
OT  - mRNA translation
OT  - mTOR
EDAT- 2017/11/19 06:00
MHDA- 2019/09/13 06:00
PMCR- 2019/01/01
CRDT- 2017/11/19 06:00
PHST- 2017/10/11 00:00 [received]
PHST- 2017/10/26 00:00 [revised]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/11/19 06:00 [pubmed]
PHST- 2019/09/13 06:00 [medline]
PHST- 2017/11/19 06:00 [entrez]
PHST- 2019/01/01 00:00 [pmc-release]
AID - S2212-4926(17)30170-7 [pii]
AID - 10.1016/j.jbior.2017.11.001 [doi]
PST - ppublish
SO  - Adv Biol Regul. 2018 Jan;67:30-39. doi: 10.1016/j.jbior.2017.11.001. Epub 2017 
      Nov 2.